Table 1. Deracemization of R-Substituted Phenylacetic Acids by the Aid of the Enzyme System of N. diaphanozonaria
c
entry
starting compd
(()-1a
(R)-1a (88% ee)
(S)-1a (93% ee)
(()-1be (D content: 98%)
(()-1ce (D content: 100%)
(()-1d
reactn time (h)
producta
yieldb (%)
[R]D
eed (%)
1
2
3
4
5
6
7
48
48
48
48
48
16
48
(R)-1a
(R)-1a
(R)-1a
81
58
48
66
61
58
74
-71.3
69
72
52
78
71
6
(R)-1a e (D content: 20%)
(R)-1a e (D content: 100%)
(R)-1c
-5.6
(()-1e
(R)-1d
55
a The corresponding starting compounds were incubated with grown cells of N. diaphanozonaria at 30 °C. b Isolated yield after conversion to the
corresponding methyl ester by treatment with diazomethane. c Optical rotation was measured in EtOH, c ) 1.00-1.03 after conversion to the corresponding
methyl ester. d ee (%) of the product was determined by HPLC analysis after conversion to the corresponding methyl ester. e D content was calculated from
1H NMR analysis.
compounds, and some of these approaches have been
previously reported.4,5
the inversion of the chirality of 2-phenylpropanoic acid from
(S)- to the (R)-configuration. To the best of our knowledge,
this is the first example of inverting the chirality of
2-arylpropanoic acid derivatives from S to R.
Only a few reports are known for the enzymatic derace-
mization of 2-arylpropanoic acid, i.e., the use of rat liver6,7
and two fungi, Cordyceps militaris3,8 and Verticillium leca-
nii,9 which are capable of inverting the chirality of 2-aryl-
propanoic acid derivatives from the (R)-enantiomer to its (S)-
antipode. In this case, the mechanism of the biotransformation
system was proposed based on various studies using enan-
tiomerically pure compounds and deuterated derivatives.3,6,8,9
These studies, however, have been carried out from the
perspective of the pharmacological effect of racemic com-
pounds and were intended to clarify the destiny of two
enantiomers in vivo. As described above, this type of reaction
is also interesting from the standpoint of synthetic chemistry.
Thus, we tried to examine the applicability of such a novel
type of reaction as well as the substrate specificities and
mechanism of the reaction.
The best incubation conditions so far obtained for 2-
phenylpropanoic acid are as follows. To 90 mL of a nutrient
medium was added a suspension of 48 h incubated cells of
N. diaphanozonaria in 10 mL of broth, and the incubation
was carried out at 30 °C for 24 h (first incubation). Then,
0.1% w/v of (()-2-phenylpropanoic acid was added to the
suspension of the grown cells, and the mixture was shaken
for another 48 h (second incubation). Extraction of the broth,
followed by treatment with diazomethane and subsequent
purification of the product, gave the methyl ester of the
starting acid. The yield and enantiomeric excess were
determined to be 81% and 69% (R), respectively. Elongation
of the time of the second incubation resulted in the
remarkable decrease of the yield and enantiomeric excess
of the product.
There are two possible paths for the asymmetrization of
the substrates. One is deracemization of the substrate via
some mechanism and the other is the enantioselective
degradation of the (S)-enantiomer. The latter is supposed to
be a minor path, if at all, based on the yield and the ee
mentioned above. To clarify, if the enantioselective degrada-
tion path was actually working, optically active 2-phenyl-
propanoic acid was subjected to the reaction (Table 1).
Regardless of the configuration of the starting material (88%
R or 93% S), the recovery of the product was around 70%
and the configuration was R (72% ee from R and 52% ee
from S-starting acid). These results indicate that the enan-
tioselective degradation process is very unlikely in this
system. In addition, when (()-2-deuterio-2-phenylpropanoic
acid (D content 98%) was incubated with the whole cells of
After some screening, we found a deracemization activity
in a type of actinomycetes, Nocardia diaphanozonaria JCM
3208.10 The enzyme system of N. diaphanozonaria catalyzes
(3) Rhys-Williams, W.; McCarthy, F.; Backer, J.; Hung, Y.-F.; Thoma-
son, M. J.; Lloyd, A. W.; Hanlon, G. W. Enzyme Microb. Technol. 1998,
22, 281-287 and reference cited therein.
(4) (a) Wu, S.-H.; Guo, Z.-W.; Sih, C. J. J. Am. Chem. Soc. 1990, 112,
2, 1990-1995. (b) Cambou, B.; Klibanov, A. M. Biotechnol. Bioeng. 1984,
XXVI, 1449-1454. (c) Liu, Y.-Y.; Xu, J.-H.; Hu, Y. J. Mol. Catal. B:
Enzymol. 2000, 10, 523-529.
(5) Colton, I. J.; Ahmed, S. N.; Kazlauskas, R. J. J. Org. Chem. 1995,
60, 212-217.
(6) (a) Knihinicki, R. D.; Day, R. O.; Williams, K. M. Biochem.
Pharmacol. 1991, 42, 1905-1911. (b) Knights, K.; Talbot, U. M.; Baillie,
T. A. Biochem. Pharmacol. 1992, 44, 2415-2417. (c) Menzel, S.; Waibel,
R.; Brune, K.; Geisslinger, G. Biochem. Pharmacol. 1994, 48, 1056-1058.
(7) (a) Shieh, W.-R.; Chen, C.-S. J. Biol. Chem. 1993, 268, 3487-3493.
(b) Brugger, R.; Al´ıa, B. G.; Reichel, C.; Waibel, R.; Menzel, S.; Brune,
K.; Geisslinger, G. Biochem. Pharmacol. 1996, 52, 1007-1013. (c) Reichel,
C.; Brugger, R.; Bang, H.; Geisslinger, G.; Brune, K. Mol. Pharmacol. 1997,
51, 576-582.
(8) Rhys-Williams, W.; Thomason, M. J.; Hung, Y.-F.; Hanolon, G. W.;
Lloyd, A. W. Chirality 1998, 10, 528-534.
(9) Rhys-Williams, W.; Thomason, M. J.; Lloyd, A. W.; Hanlon, G. W.
Pharm. Sci. 1996, 2, 537-540.
(10) The strain used in this experiment is available from the Japan
Collection of Microorganism: The Institute of Physical and Chemical
Research (Riken), 2-1 Hirosawa, Wako 351-0106, Japan.
372
Org. Lett., Vol. 4, No. 3, 2002